基于胸部计算机断层扫描的定量与定性肌肉质量评估在系统性硬化症患者中的应用:一项横断面与纵向分析的回顾性研究
该回顾性研究连续纳入2012至2021年某三级大学医院门诊的系统性硬化症患者,用胸部CT在L1层面测量骨骼肌面积、骨骼肌指数和骨骼肌放射衰减,并与双能X线吸收法测定的四肢骨骼肌质量指数比较。结果显示SMA是检测肌少症(myopenia)的准确指标,BMI和女性性别与SMA定义的肌少症显著相关。
要点
- 系统性硬化症患者中肌少症和/或肌脂增多症(myosteatosis)的总体患病率为75.7%。
- 以ASMI为金标准,SMA的敏感度60%、特异度96.2%、阳性预测值75%、阴性预测值92.6%。
- 多因素模型中BMI(p<0.001)和女性性别(p<0.001)与SMA定义的肌少症显著相关。
核心结论
- 胸部CT在L1层面测量的SMA被证明是检测系统性硬化症患者肌少症的准确且有用的指标。
- BMI和男性性别可预测低SMA,BMI与DXA测定的低ASMI相关。
研究设计与样本
- 回顾性研究,包含横断面和纵向分析,连续纳入2012年至2021年某三级大学医院门诊的系统性硬化症患者。
- 在31例于2017年至2019年随访的患者亚组中,将CT测量的SMA、SMI和SMRA与DXA测定的ASMI进行比较。
- 低肌肉量依据欧洲老年人肌少症工作组2(EWGSOP2)定义:女性ASMI<5.5 kg/m²,男性<7.0 kg/m²。
主要发现
- 肌少症和/或肌脂增多症存在于75.7%的系统性硬化症患者中;各指标患病率分别为SMA 25.2%、SMI 12.1%、SMRA 69.2%。
- 在73%的超重/肥胖(BMI≥25 kg/m²)患者中,仅SMRA降低。
- 以ASMI为金标准,SMA的敏感度、特异度、阳性预测值和阴性预测值分别为60%、96.2%、75%和92.6%;SMI分别为40%、96.2%、66.7%和89.3%;SMRA分别为60%、34.6%、15%和81.8%。
- SMA、SMI和SMRA与ASMI的Pearson相关系数分别为0.73、0.74和0.10;ASMI与SMA显著一致(kappa 0.611,p<0.001),与SMI显著一致(kappa 0.431,p=0.012)。
- 多因素模型调整后,BMI(p<0.001)和女性性别(p<0.001)仍与SMA定义的肌少症显著相关;BMI(p=0.010)仍与ASMI定义的低肌肉量显著相关。
关键数值与推荐
- 女性肌少症截断值:SMA<70.1 cm²,SMI<25.9 cm²/m²;男性:SMA<110.4 cm²,SMI<34.6 cm²/m²。
- 女性肌脂增多症截断值:SMRA<29.8 HU;男性:SMRA<36.3 HU。
- 低肌肉量定义依据EWGSOP2:女性ASMI<5.5 kg/m²,男性<7.0 kg/m²。
临床怎么用
- 作者指出,尽管CT上无L3层面图像,胸部CT L1层面SMA分析被证明是检测系统性硬化症患者肌少症的准确且有用的测量方法。
- 作者强调在评估身体成分影像参数的临床研究中不应将「肌少症」一词泛化,使用肌少症和/或肌脂增多症更为合适,因为CT可评估肌肉组成而非肌力或躯体功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/ PURPOSE: Sarcopenia has been increasingly studied in systemic sclerosis (SSc), which is one of the most lethal autoimmune diseases, mainly due to lung involvement. Our objective was to study the associations of myopenia and/or myosteatosis with clinical features of SSc and subsequent adverse outcomes. METHODS: This is a retrospective study with cross-sectional and longitudinal analyses, in which patients with SSc were consecutively included in the outpatient clinic of a tertiary university hospital between 2012 and 2021. Clinical and laboratory parameters of patients with SSc were collected from their medical records. Skeletal muscle mass was assessed on chest computed tomography (CT) at the level of the first lumbar vertebra (L1) by skeletal muscle area (SMA), skeletal muscle index ([SMI] SMA/height2), and skeletal muscle radiation attenuation (SMRA). Cut-off values for myopenia in women and men were SMA <70.1 cm² and <110.4 cm², and SMI <25.9 cm²/m² and <34.6 cm²/m², respectively; values for myosteatosis in women and men were SMRA <29.8 HU and <36.3 HU, respectively. In a subgroup of 31 patients followed-up between 2017 and 2019, the diagnostic properties of SMA, SMI, and SMRA by CT were compared with the appendicular skeletal muscle mass index (ASMI) by dual-energy X-ray absorptiometry (DXA). Low muscle quantity was defined according to the European Working Group on Sarcopenia in Older People 2: ASMI <5.5 kg/m2 in women and <7.0 kg/m2 in men. Afterwards, a better tomographic index was used for correlating with clinical and laboratory parameters. RESULTS: Myopenia and/or myosteatosis were present in 75.7 % of patients with SSc. The prevalence rates according to each index were SMA 25.2%, SMI 12.1%, and SMRA 69.2%. In 73% of the patients with overweight/obesity (body mass index [BMI] ≥25 kg/m²), only SMRA was reduced. Considering ASMI as the gold standard, the sensitivity, specificity, positive and negative predictive values for SMA were 60%, 96.2%, 75% and 92.6%, respectively; for SMI, they were 40%, 96.2%, 66.7%, and 89.3%, respectively; for SMRA, these values were 60%, 34.6%, 15%, and 81.8%. Pearson's correlation coefficients were 0.73, 0.74, and 0.10 for SMA, SMI, and SMRA, respectively, and ASMI significantly agreed with SMA (kappa 0.611, p < 0.001) and SMI (kappa 0.431, p = 0.012). After adjustments in a multivariate model, BMI (p < 0.001) and female sex (p < 0.001) remained significantly associated with myopenia by SMA; BMI (p =0.010) remained significantly associated with low muscle mass by ASMI. CONCLUSION: The SMA index at L1 level on chest CT was demonstrated to be an accurate measure that is useful for detecting myopenia in patients with SSc. BMI and male sex predicted low SMA and BMI was associated with low ASMI on DXA. STATEMENT OF CLINICAL SIGNIFICANCE: In recent years, great advances have been made in sarcopenia-related research, resulting in broader knowledge on its definition, causes, diagnosis, and treatment options. Regarding the techniques used for assessing muscle composition, computed tomography (CT) was demonstrated by many studies to be an efficient and easy-to-use method that can be employed by professionals of different specialties, including rheumatologists. This study was able to demonstrate that although the L3 image was not present on CT, the analysis of SMA at the L1 level on chest CT proved to be an accurate and useful measure to detect myopenia in patients with SSc. This study identified some associated factors of myopenia and/or myosteatosis according to each method employed for assessing muscle composition. Reduced BMI and male sex were associated factors of myopenia when using SMA, and reduced BMI was associated with myopenia when employing ASMI by DXA. Finally, we highlight the need not to generalize the term "sarcopenia" in clinical studies assessing imaging parameters of body composition. The use of the terms myopenia and/or myosteatosis would be more adequate, because CT allows the assessment of muscle composition and not strength or physical performance.
引用
- da Rocha DS, Tessari JA, Mainardi NB, et al. Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses. Semin Arthritis Rheum. 2023. PMID: 36736023. doi:10.1016/j.semarthrit.2023.152168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。